Publications by authors named "Helene Negre"

Claim this Profile
P
Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe.
Elise R A Pennings, Anne M Spanjaart, Frederick W Thielen, Simone Oerlemans, Anna Fleischer, Hélène Negre

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European survey on CAR T-Cell analytical methods from apheresis to post-infusion immunomonitoring.
Biagio De Angelis, Maria Luisa D'Amore, Pacôme Lecot, Kerstin Neininger, Margot Lorrain, Helene Negre

Front Immunol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimizing CAR-T treatment: A TEVOLVE guide to raw and starting material selection.
Sergio Navarro, Carole Moukheiber, Susana Inogés Sancho, Marta Ruiz Guillén, Ascensión López-Díaz de Cerio, Hélène Negre

Mol Ther· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cultivated autologous limbal epithelial cell (CALEC) transplantation for limbal tem cell deficiency: a phase I/II clinical trial of the first xenobiotic-free, serum-free, antibiotic-free manufacturing protocol developed in the US.
Ula V Jurkunas, Aaron R Kaufman, Jia Yin, Allison Ayala, Maureen Maguire, Helene Negre

Nat Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic B cell immunomodulatory therapy in amyotrophic lateral sclerosis.
Ruxandra F Sîrbulescu, Katharine Nicholson, Kento Kawai, Orla M Hilton, Don Sobell, Hélène Negre

FASEB J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle.
Benno Lickefett, Lulu Chu, Valentin Ortiz-Maldonado, Linda Warmuth, Pere Barba, Helene Negre

Front Immunol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations.
Delphine Ammar, Inga Schapitz, Maik Luu, Michael Hudecek, Miriam Meyer, Helene Negre

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cultivated autologous limbal epithelial cell (CALEC) transplantation: Development of manufacturing process and clinical evaluation of feasibility and safety.
Ula V Jurkunas, Jia Yin, Lynette K Johns, Sanming Li, Helene Negre

Sci Adv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
10th antibody industrial symposium: new developments in antibody and adoptive cell therapies.
Ana Antunes, Luis Alvarez-Vallina, Federico Bertoglio, Nicolas Bouquin, Stéphanie Cornen, Hélène Negre

MAbs· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Emmanuel Donnadieu, Maik Luu, Miriam Alb, Brigitte Anliker, Silvia Arcangeli, Helene Negre

J Immunother Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-Transcriptional Genetic Silencing of to Treat Sickle Cell Disease.
Erica B Esrick, Leslie E Lehmann, Alessandra Biffi, Maureen Achebe, Christian Brendel, Helene Negre, Olivier Negre

N Engl J Med· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis